Time to reset economy

Get App

Time to reset economy

you are here: HomeNewsBusinessIPO
Last Updated : Jan 07, 2020 09:29 PM IST | Source: Moneycontrol.com

Reporter's Take | Why Biocon Biologics is valued at $3 bn?

Moneycontrol’s Jerome Anthony talks to pharma correspondent Viswanath Pilla to find out why the company has received such a high valuation.

Biocon Biologics has been valued at a whopping $3 billion after it managed to raise Rs 530 crore from a domestic private equity fund. The Biocon arm is now valued at almost 60 percent of the parent company.

India’s fast-growing biosimilar company accounted for a third of the company’s consolidated revenues for H1FY20 and recently launched 3 biosimilars in highly regulated international markets.

In this episode of Editor’s Take, Moneycontrol’s Jerome Anthony talks to pharma correspondent Viswanath Pilla to find out why the company has received such a high valuation.

Close
Watch the video for more.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Jan 7, 2020 09:29 pm
Sections
Follow us on